AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1769410
Drug: Papaverine hydrochloride
RxNorm normalized name: Papaverine Hydrochloride
DrugBank: Papaverine (DB01113)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Papaverine hydrochloride (150-300 mg t.i.d.)
Trial: 7107102
Drug: Fixed Anaerobic
RxNorm normalized name: Peptostreptococcus anaerobius
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed Anaerobic Threshold of 4 mmol.l(-1) lactate (ATc)
Trial: 31682026
Drug: 1-L PEG,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-L PEG, 4 h before VCE
Trial: 31682026
Drug: 1-L PEG,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-L PEG, 12 h before VCE
Trial: 31682026
Drug: 2-L PEG,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-L PEG, 12 h before VCE
Trial: 31682026
Drug: 2-L PEG,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-L PEG, 4 h before VCE
Trial: 28035924
Drug: Donepezil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (10 mg/day) plus Choline Alphoscerate (1200 mg/day)
Trial: 28035924
Drug: Donepezil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (10 mg/day) plus Placebo
Trial: 26310362
Drug: Active Treatment
RxNorm normalized name: Active
DrugBank: Octisalate (DB11062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active Treatment Condition (ATC)
Trial: 19514089
Drug: EGF 50
RxNorm normalized name: ABX-EGF
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: EGF 50 microg/mL
Trial: 17543813
Drug: 0.25% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% levobupivacaine as a bolus and/or 50‐hour infusion
Trial: 8573702
Drug: Feedback of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feedback of eye movements treatment (wearing glasses providing a reminder bleep if patients failed to move their eyes to the left in a 15 s interval) for 2 h 40 min a week for 4 weeks.
Trial: 8573702
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment for visual inattention).
Trial: 2677240
Drug: Brofaromine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brofaromine (25 mg bid, 50 mg bid, 75 mg bid)
Trial: 2677240
Drug: Tranylcypromine 20
RxNorm normalized name: tranylcypromine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tranylcypromine 20 mg/day
Trial: 2677240
Drug: Nomifensine 100
RxNorm normalized name: nomifensine
DrugBank: Nomifensine (DB04821)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nomifensine 100 mg/day
Trial: 25050869
Drug: Amlodipin (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipin (5-10 mg/d)
Trial: 25050869
Drug: Verapamil (120-240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (120-240 mg/d)
Trial: 23556460
Drug: Fiber supplements
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiber supplements (GA, PSY, CMC)
Trial: 21931737
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) rAd5 vaccine boost
Trial: 21931737
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) rAd5 vaccine boost
Trial: 21931737
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) rAd5 vaccine boost
Trial: 21931737
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not receiving rAd5 vaccine boost)
Trial: 17240799
Drug: Chemoradiotherapy (radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy (radiotherapy plus injection cisplatin 30 mg/m2 once weekly for 5 weeks)
Trial: 12788885
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg DHEA after 4 days of dexamethasone (Dex; 4 x 0.5 mg/d)
Trial: 12788885
Drug: Dexamethasone (Dex;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (Dex; 4 x 0.5 mg/d)
Trial: 12788885
Drug: Placebo after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo after 4 days of dexamethasone (Dex; 4 x 0.5 mg/d)
Trial: 8972377
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection (0.5 ml of balanced salt solution) for conjunctival wound closure (Group B)
Trial: 8972377
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection (Group B)
Trial: 1358607
Drug: Ondansetron 16
RxNorm normalized name: ondansetron 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 16 mg three times daily
Trial: 4089582
Drug: timolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: timolol (10 mg/d, n = 14)
Trial: 4089582
Drug: methyldopa (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methyldopa (250 mg/d, n = 16)
Trial: 4089582
Drug: hydrochlorothiazide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrochlorothiazide (25 mg/d) and amiloride (2.5 mg/d)
Trial: 22683613
Drug: Plerixafor plus
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plerixafor plus granulocyte colony-stimulating factor (G-CSF)
Trial: 22683613
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus granulocyte colony-stimulating factor (G-CSF)
Trial: 16124423
Drug: Rectal artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rectal artesunate (initial dose of 40 mg/kg bodyweight, in 3 or 4 divided doses in the first 24 hours, followed by 10 mg/kg bodyweight once daily for three consecutive days)
Trial: 16124423
Drug: Rectal artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rectal artesunate (high initial dose regimen of 20 mg/kg bodyweight)
Trial: 8334064
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of atenolol 50 mg and nifedipine retard 20 mg (Tenif) once daily
Trial: 29775957
Drug: MAS‐XR (60mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAS‐XR (60mg or 80mg daily)
Trial: 27132212
Drug: MAGE‐A3 immunotherapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAGE‐A3 immunotherapeutic (no chemotherapy)
Trial: 27132212
Drug: Placebo (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (no chemotherapy)
Trial: 11778184
Drug: Levofloxacin (LVLX)
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin (LVLX) at a dose of 300 mg/d
Trial: 11778184
Drug: Ofloxacin (OFLX)
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ofloxacin (OFLX) at a dose of 600 mg/d
Trial: 6695025
Drug: Silicone-gel prostheses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone-gel prostheses
Trial: 22028294
Drug: Personalized therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized therapy based on ERCC1 and RRM1 expression
Trial: 22028294
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (Trial A, B, C)
Trial: 18074942
Drug: Myo-inositol plus
RxNorm normalized name: myo-inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Myo-inositol plus folic acid (4 g myo-inositol plus 400 mcg folic acid)
Trial: 18074942
Drug: Placebo (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (400 mcg folic acid)
Trial: 2296878
Drug: Diltiazem, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem, 60 mg three times daily
Trial: 2296878
Drug: Nifedipine, 10
RxNorm normalized name: Nifedipine, 10 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine, 10 mg three times daily
Trial: 25464907
Drug: UMEC 15.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UMEC 15.6 mcg once daily (OD)
Trial: 25464907
Drug: UMEC 125
RxNorm normalized name: Umecta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UMEC 125 mcg once daily (OD)
Trial: 25464907
Drug: UMEC (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UMEC (various doses)
Trial: 23305962
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (in concurrent study)
Trial: 21353673
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg letrozole daily for 7 days
Trial: 19152549
Drug: Nabumetone 1
RxNorm normalized name: nabumetone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabumetone 1 g
Trial: 17415139
Drug: Pulse therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse therapy (300 mg dexamethasone for 3 consecutive days followed by 4 days of placebo)
Trial: 17415139
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (prednisone 70 mg per day tapered in steps of 10 mg per day to 0 mg)
Trial: 16506546
Drug: DEC +
RxNorm normalized name: Zodryl DEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEC + Ivermectin 200mcg (6mg/kg body weight + 200 mcg/kg body weight)
Trial: 16506546
Drug: DEC +
RxNorm normalized name: Zodryl DEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEC + Ivermectin 400mcg (6mg/kg body weight + 400 mcg/kg body weight)
Trial: 17671254
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone (200 mg each night) from 24 to 34 weeks of gestation
Trial: 17671254
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone (200 mg each night)
Trial: 8723580
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (300 or 600 IU/kg) administered three times (days 1, 4, and 7)
Trial: 6125676
Drug: Amoxycillin 500
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 500 mg and clavulanic acid 125 mg
Trial: 6125676
Drug: Amoxycillin 500
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 500 mg and clavulanic acid 250 mg
Trial: 6125676
Drug: Amoxycillin 500
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 500 mg
Trial: 25247908
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% + 1 μg/kg dexmedetomidine (Group BD)
Trial: 20605648
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBO) - 100% oxygen at 2.4 atmospheres absolute for 100 min on 30 occasions over 6 weeks.
Trial: 16075824
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment in Northern Americas (NA)
Trial: 16075824
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment in Caribbean (CA)
Trial: 16075824
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment in Eurasia (EA)
Trial: 12436031
Drug: Prophylactic barbiturate
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic barbiturate therapy
Trial: 12436031
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate and calcium channel blockers
Trial: 2106545
Drug: Daily infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily infusions of 200 cc of a 20% lipid emulsion with TPN for the first week, followed by daily intravenous lipid for the next 3 weeks (0.7 g lipid/kg BW/day and approximately 280 mg of choline/day)
Trial: 2106545
Drug: TPN without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPN without lipid for the first week, followed by daily intravenous lipid for the next 3 weeks
Trial: 31471494
Drug: Subcutaneous needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous needle drainage
Trial: 27143873
Drug: Lysozyme (270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysozyme (270 mg) administered orally for 52 weeks as an add-on to standard therapies
Trial: 27143873
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally for 52 weeks as an add-on to standard therapies
Trial: 19963442
Drug: Insulin-resistant subjects
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-resistant subjects with impaired fasting glycaemia (IFG)
Trial: 19963442
Drug: Insulin-resistant subjects
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-resistant subjects with normal glucose regulation (NGR)
Trial: 15721501
Drug: Egg ingestion
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egg ingestion (2 eggs daily for 6 weeks)
Trial: 15721501
Drug: Oat ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat ingestion (oats daily for 6 weeks)
Trial: 7611203
Drug: Bismuth subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subsalicylate (524 mg q.i.d.) and metronidazole (250 mg q.i.d. for the first 2 weeks) for 4 weeks
Trial: 628361
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g probenecid
Trial: 628361
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day benzbromaron
Trial: 628361
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day benzbromaron
Trial: 628361
Drug: 2 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/day probenecid
Trial: 30635187
Drug: Trifecta biological
RxNorm normalized name: Trifena
DrugBank: (+)-menthol (DB11344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifecta biological valve
Trial: 30635187
Drug: Mosaic Ultra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosaic Ultra biological valve
Trial: 18445058
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (N/S) infusion at a rate of 800 ml/hour during DSE
Trial: 15943850
Drug: famotidine 20
RxNorm normalized name: famotidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine 20 mg bd
Trial: 7564481
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of oral methotrexate weekly
Trial: 7006657
Drug: dezocine 5
RxNorm normalized name: dezocine 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dezocine 5 mg
Trial: 7006657
Drug: dezocine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dezocine (all doses)
Trial: 25622538
Drug: Guanidinoacetic acid
RxNorm normalized name: Guanidinoacetic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanidinoacetic acid (GAA) 1.2 g
Trial: 25622538
Drug: Guanidinoacetic acid
RxNorm normalized name: Guanidinoacetic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanidinoacetic acid (GAA) 2.4 g
Trial: 25622538
Drug: Guanidinoacetic acid
RxNorm normalized name: Guanidinoacetic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanidinoacetic acid (GAA) 4.8 g
Trial: 18838053
Drug: Teriparatide 20
RxNorm normalized name: TERIPARATIDE 200UNT/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide 20 µg/day for one year
Trial: 16026869
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg/day, 300 mg loading dose within 24 h prior to hospital admission) plus standard therapy (including ASA, 75‐325 mg/day) for 1 year
Trial: 16026869
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy alone (including ASA, 75‐325 mg/day) for life
Trial: 15556258
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (600 IU=540 mg vitamin E emulsion)
Trial: 2894219
Drug: Nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 10 and 20 mg
Trial: 25100106
Drug: Subcutaneous progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous progesterone (Prolutex) 25 mg daily
Trial: 25100106
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone (Endometrin) 100 mg bid daily
Trial: 25100106
Drug: Subcutaneous progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous progesterone (Prolutex)
Trial: 22497752
Drug: Aclidinium 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclidinium 100 μg
Trial: 18281658
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg orally daily until progression
Trial: 18281658
Drug: Carboplatin (AUC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (AUC 6) and paclitaxel (200 mg/m² day 1 every 3 weeks) for up to four cycles
Trial: 10942632
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment (9.5 microg/kg/day) for 9 months
Trial: 8630191
Drug: Intensive outpatient
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive outpatient therapy (1 hr each of physical and occupational therapy, four times per week, for 12 weeks)
Trial: 8630191
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment supplied)
Trial: 8400928
Drug: levodopa/dopa decarboxylase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levodopa/dopa decarboxylase inhibitor alone (arm 1)
Trial: 8400928
Drug: levodopa/decarboxylase inhibitor/selegiline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levodopa/decarboxylase inhibitor/selegiline in combination (arm 2)
Trial: 3553802
Drug: Killed, armadillo-derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Killed, armadillo-derived M. leprae vaccine (1.5 x 10^7 bacilli)
Trial: 3553802
Drug: Killed, armadillo-derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Killed, armadillo-derived M. leprae vaccine (5 x 10^7 bacilli)
Trial: 3553802
Drug: Killed, armadillo-derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Killed, armadillo-derived M. leprae vaccine (1.5 x 10^8 bacilli)
Trial: 3553802
Drug: Killed, armadillo-derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Killed, armadillo-derived M. leprae vaccine (5 x 10^8 bacilli)
Trial: 21391924
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) - 100 mg/kg bolus IV over 15 min, followed by 40 mg/kg/day IV infusion for 24 h
Trial: 19364873
Drug: Sulfadoxine-pyrimethamine (SP)
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine-pyrimethamine (SP) single-dose treatment
Trial: 15084901
Drug: Nefazodone (200-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone (200-600 mg/day)
Trial: 9771299
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml kg‐1 of crystalloid fluid preload over 20 min
Trial: 7830390
Drug: Carbohydrate maltodextrin
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate maltodextrin supplement (MD; 5% maltodextrin + 2% fructose) at dosage of 0.25 g.kg‐1 body weight (mean intake rate, total: 37 g.h‐1, 148 g)
Trial: 7830390
Drug: Carbohydrate maltodextrin
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate maltodextrin supplement (MD)
Trial: 3034318
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg once daily
Trial: 3071596
Drug: Captopril 100
RxNorm normalized name: captopril 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 100 mg once daily
Trial: 27933698
Drug: Sofosbuvir 400
RxNorm normalized name: sofosbuvir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir 400 mg and weight-based ribavirin (1000 or 1200 mg) daily for 16 weeks
Trial: 27933698
Drug: Sofosbuvir 400
RxNorm normalized name: sofosbuvir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir 400 mg and weight-based ribavirin (1000 or 1200 mg) daily for 24 weeks